Developer docs
API playgroundTry for free, no card

Search company profiles

Acurx Pharmaceuticals

Full company profile

uuid000078n

Namestring
Acurx Pharmaceuticals
Legal namestring
Acurx Pharmaceuticals, Inc.
Websiteurl
acurxpharma.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a publicly traded, clinical-stage biopharmaceutical company headquartered in Staten Island, New York (Delaware-incorporated), developing a new class of small-molecule antibiotics that inhibit DNA polymerase IIIC (PolC), an enzyme specific to Gram-positive bacteria. The company's proprietary platform, branded Gram-Positive Selective Spectrum (GPSS®), blocks bacterial DNA replication while sparing beneficial gut microbiota, addressing the high recurrence rates (20-40%) and microbiome disruption associated with current standard-of-care antibiotics for C. difficile infection (CDI). Lead candidate ibezapolstat has completed Phase 2 trials showing a 96% clinical cure rate with 0% recurrence in cured patients, has received FDA QIDP and Fast Track designations and EMA SME designation, and is Phase 3-ready with regulatory alignment from both FDA and EMA. A preclinical pipeline (ACX-375C) extends the platform to systemically absorbed antibiotics against MRSA, VRE, drug-resistant Streptococcus pneumoniae, and inhalational anthrax.

Short descriptiontext

Acurx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company developing a new class of DNA polymerase IIIC (PolC) inhibitor antibiotics, with lead candidate ibezapolstat Phase 3-ready for C. difficile infection and preclinical assets targeting MRSA, VRE, and anthrax.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStaten Island, United States
HQ citystring
Staten Island
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibiotic drug development, clinical stage biopharmaceutical, Gram-positive infections, DNA polymerase inhibitors, C. difficile treatment
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics (Antibiotics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Antibiotic commercialization
TypeOne Time License
Description

Acurx is a pre-revenue clinical-stage biopharmaceutical company. Its primary anticipated revenue stream will come from the commercialization of its antibiotic pipeline following regulatory approval, starting with ibezapolstat for C. difficile infection (CDI). The company is developing antibiotics for acute CDI, recurrent CDI (rCDI), and other Gram-positive bacterial infections including MRSA, VRE, and anthrax. Revenue will be generated through pharmaceutical product sales once approved.

acurxpharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1GPSS®
Description

Gram-Positive Selective Spectrum - the company's antibiotic development approach targeting DNA polymerase IIIC in Gram-positive bacteria while sparing beneficial gut microbiota

ir.acurxpharma.com
+1 more record
Core offering1 text field

Acurx Pharmaceuticals develops a new class of small-molecule antibiotics that inhibit the Gram-positive specific enzyme DNA polymerase IIIC (PolC), marketed under its Gram-Positive Selective Spectrum (GPSS®) approach. Its lead asset, oral ibezapolstat, is a Phase 3-ready antibiotic for C. difficile infection (CDI), and the preclinical ACX-375C program extends the same platform to systemically absorbed treatments for MRSA, VRE, drug-resistant Streptococcus pneumoniae, and inhalational anthrax.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 96% clinical cure rate (25 of 26 patients) in combined Phase 2 trials for CDI
+3 more records
Product overview1 text field

Acurx Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of antibiotics targeting priority pathogens identified by WHO, CDC, and FDA. The company operates a GPSS® (Gram-Positive Selective Spectrum) technology platform with its lead product ibezapolstat in Phase 3 ready status for C. difficile infection treatment. The preclinical pipeline includes the ACX-375C program for systemically absorbed antibiotics targeting MRSA, VRE, DRSP, and anthrax. The company leverages DNA polymerase IIIC inhibition as a novel mechanism of action.

Product and service2 records
1Ibezapolstat (IBZ)
CategoryLead clinical antibiotic candidate (oral, CDI)
Description

Oral, first-in-class DNA polymerase IIIC inhibitor antibiotic being developed for the treatment of C. difficile infection (CDI), including prevention of recurrent CDI. Phase 3-ready with FDA QIDP and Fast Track designations; intended for hospital initiation and outpatient continuation in patients with acute and multiply-recurrent CDI.

2ACX-375C Program
CategoryPreclinical systemic antibiotic pipeline (Gram-positive infections)
Description

Preclinical pipeline of systemically absorbed DNA Pol IIIC inhibitors designed to treat serious drug-resistant Gram-positive bacterial infections including MRSA, VRE, drug-resistant Streptococcus pneumoniae (DRSP), and Bacillus anthracis (anthrax). Targets indications where existing antibiotic classes are failing and where new mechanism-of-action therapies are needed.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Acurx Pharmaceuticals collaborates with Leiden University Medical Center (LUMC) in the Netherlands on research into DNA Pol IIIC inhibitors. This is a public-private partnership (PPP) partially funded by Health~Holland (Dutch government research grant of approximately $375,000 USD). The collaboration has resolved the cryo-EM structure of ibezapolstat bound to DNA pol IIIC at 3.2Å resolution. The new grant (POLSTOP4MDRO) aims to study mode-of-action and resistance conservation across MRSA, VRE, and PRSP, and to generate the first-ever 3D structure of PolC from MRSA in complex with an Acurx inhibitor. Lead researchers include Dr. Wiep Klaas Smits, Dr. Meindert Lamers, and Dr. Mia Urem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage microbiome therapeutics company that developed and commercialized Vowst, the first FDA-approved oral microbiome therapeutic for prevention of recurrent C. difficile infection. Directly comparable to Acurx as both target CDI/rCDI with differentiated mechanisms.

TypeBroad incumbent
Description

Global specialty biopharmaceutical company that markets Rebyota (fecal microbiota, live-jslm), the first FDA-approved fecal microbiota product for prevention of rCDI. Comparable as an established CDI/rCDI player competing in Acurx's core therapeutic area.

TypeBroad incumbent
Description

Large pharmaceutical company that markets Dificid (fidaxomicin), the leading branded macrocyclic antibiotic for C. difficile infection. Comparable as the entrenched standard-of-care competitor that any new CDI entrant (including ibezapolstat) must displace.

TypeBroad incumbent
Description

Japanese multinational pharmaceutical company that co-markets Dificid (fidaxomicin) with Merck for CDI. Comparable as a broad incumbent selling an established CDI therapy competing with Acurx's lead candidate.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing oral sulopenem for complicated urinary tract infections and other Gram-negative infections. Comparable as a small-cap, late-stage antibiotics developer with similar capital-raising profile and reliance on a single late-stage asset.

TypeDirect peer
Description

Clinical-stage biotechnology company developing anti-infectives including rezafungin, a long-acting echinocandin antifungal. Comparable as a small public anti-infectives developer focused on differentiated mechanism and hospital use.

TypeDirect peer
Description

Specialty antibiotics company with marketed products including Baxdela (delafloxacin). Comparable as a small antibiotics-focused commercial-stage company navigating the same hospital-channel commercial dynamics relevant to a future ibezapolstat launch.

8Nabriva Therapeutics
TypeDirect peer
Description

Biopharmaceutical company that developed and commercialized Xenleta (lefamulin), a pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable as a small-cap antibiotics developer with a hospital-channel launch approach and similar regulatory pathway profile.

TypeDirect peer
Description

Specialty pharmaceutical company that acquired Entasis Therapeutics and commercialized Xacduro (sulbactam-durlobactam) for Acinetobacter infections. Comparable as a focused anti-infectives developer targeting serious bacterial pathogens in the hospital channel.

TypeEmerging player
Description

Clinical-stage biotechnology company developing direct lytic agents (lysins) and other anti-infectives for serious bacterial infections including drug-resistant Staphylococcus aureus. Comparable as a small emerging anti-infectives developer pursuing novel mechanisms against Gram-positive priority pathogens.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acurx Pharmaceuticals

Infectious Disease Therapeutics (Antibiotics)acurxpharma.com

Acurx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company developing a new class of DNA polymerase IIIC (PolC) inhibitor antibiotics, with lead candidate ibezapolstat Phase 3-ready for C. difficile infection and preclinical assets targeting MRSA, VRE, and anthrax.

What Acurx Pharmaceuticals does

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a publicly traded, clinical-stage biopharmaceutical company headquartered in Staten Island, New York (Delaware-incorporated), developing a new class of small-molecule antibiotics that inhibit DNA polymerase IIIC (PolC), an enzyme specific to Gram-positive bacteria. The company's proprietary platform, branded Gram-Positive Selective Spectrum (GPSS®), blocks bacterial DNA replication while sparing beneficial gut microbiota, addressing the high recurrence rates (20-40%) and microbiome disruption associated with current standard-of-care antibiotics for C. difficile infection (CDI). Lead candidate ibezapolstat has completed Phase 2 trials showing a 96% clinical cure rate with 0% recurrence in cured patients, has received FDA QIDP and Fast Track designations and EMA SME designation, and is Phase 3-ready with regulatory alignment from both FDA and EMA. A preclinical pipeline (ACX-375C) extends the platform to systemically absorbed antibiotics against MRSA, VRE, drug-resistant Streptococcus pneumoniae, and inhalational anthrax.

Acurx Pharmaceuticals firmographics

Firmographics
Name
Acurx Pharmaceuticals
Legal name
Acurx Pharmaceuticals, Inc.
Website
https://acurxpharma.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Acurx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company developing a new class of DNA polymerase IIIC (PolC) inhibitor antibiotics, with lead candidate ibezapolstat Phase 3-ready for C. difficile infection and preclinical assets targeting MRSA, VRE, and anthrax.
Ownership category
akta.pro rank

Acurx Pharmaceuticals industry classification

Industry
Product category
Infectious Disease Therapeutics (Antibiotics)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antibiotic drug development
  • Clinical stage biopharmaceutical
  • Gram-positive infections
  • DNA polymerase inhibitors
  • C. difficile treatment

Where Acurx Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Staten Island
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Acurx Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Antibiotic commercialization: Acurx is a pre-revenue clinical-stage biopharmaceutical company. Its primary anticipated revenue stream will come from the commercialization of its antibiotic pipeline following regulatory approval, starting with ibezapolstat for C. difficile infection (CDI). The company is developing antibiotics for acute CDI, recurrent CDI (rCDI), and other Gram-positive bacterial infections including MRSA, VRE, and anthrax. Revenue will be generated through pharmaceutical product sales once approved.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Acurx Pharmaceuticals product offering

Product offering

Core offering

Acurx Pharmaceuticals develops a new class of small-molecule antibiotics that inhibit the Gram-positive specific enzyme DNA polymerase IIIC (PolC), marketed under its Gram-Positive Selective Spectrum (GPSS®) approach. Its lead asset, oral ibezapolstat, is a Phase 3-ready antibiotic for C. difficile infection (CDI), and the preclinical ACX-375C program extends the same platform to systemically absorbed treatments for MRSA, VRE, drug-resistant Streptococcus pneumoniae, and inhalational anthrax.

Product overview

Acurx Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of antibiotics targeting priority pathogens identified by WHO, CDC, and FDA. The company operates a GPSS® (Gram-Positive Selective Spectrum) technology platform with its lead product ibezapolstat in Phase 3 ready status for C. difficile infection treatment. The preclinical pipeline includes the ACX-375C program for systemically absorbed antibiotics targeting MRSA, VRE, DRSP, and anthrax. The company leverages DNA polymerase IIIC inhibition as a novel mechanism of action.

Differentiator

Problem solved

Functional benefit

Brands

  • GPSS®: Gram-Positive Selective Spectrum - the company's antibiotic development approach targeting DNA polymerase IIIC in Gram-positive bacteria while sparing beneficial gut microbiota
  • ACX-375C

Products and services

  • Ibezapolstat (IBZ) Oral, first-in-class DNA polymerase IIIC inhibitor antibiotic being developed for the treatment of C. difficile infection (CDI), including prevention of recurrent CDI. Phase 3-ready with FDA QIDP and Fast Track designations; intended for hospital initiation and outpatient continuation in patients with acute and multiply-recurrent CDI.
  • ACX-375C Program Preclinical pipeline of systemically absorbed DNA Pol IIIC inhibitors designed to treat serious drug-resistant Gram-positive bacterial infections including MRSA, VRE, drug-resistant Streptococcus pneumoniae (DRSP), and Bacillus anthracis (anthrax). Targets indications where existing antibiotic classes are failing and where new mechanism-of-action therapies are needed.

Quantifiable outcome

  • 96% clinical cure rate (25 of 26 patients) in combined Phase 2 trials for CDI
  • +3 more outcomes

Companies that use Acurx Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles3 records

Acurx Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Acurx Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Leiden University Medical Center (LUMC)coreStrategic or Co-development Partner · 18 November 2025Acurx Pharmaceuticals collaborates with Leiden University Medical Center (LUMC) in the Netherlands on research into DNA Pol IIIC inhibitors. This is a public-private partnership (PPP) partially funded by Health~Holland (Dutch government research grant of approximately $375,000 USD). The collaboration has resolved the cryo-EM structure of ibezapolstat bound to DNA pol IIIC at 3.2Å resolution. The new grant (POLSTOP4MDRO) aims to study mode-of-action and resistance conservation across MRSA, VRE, and PRSP, and to generate the first-ever 3D structure of PolC from MRSA in complex with an Acurx inhibitor. Lead researchers include Dr. Wiep Klaas Smits, Dr. Meindert Lamers, and Dr. Mia Urem.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Acurx Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Seres Therapeutics: Clinical-stage microbiome therapeutics company that developed and commercialized Vowst, the first FDA-approved oral microbiome therapeutic for prevention of recurrent C. difficile infection. Directly comparable to Acurx as both target CDI/rCDI with differentiated mechanisms.
  • Iterum Therapeutics: Clinical-stage biopharmaceutical company developing oral sulopenem for complicated urinary tract infections and other Gram-negative infections. Comparable as a small-cap, late-stage antibiotics developer with similar capital-raising profile and reliance on a single late-stage asset.
  • Cidara Therapeutics: Clinical-stage biotechnology company developing anti-infectives including rezafungin, a long-acting echinocandin antifungal. Comparable as a small public anti-infectives developer focused on differentiated mechanism and hospital use.
  • Melinta Therapeutics: Specialty antibiotics company with marketed products including Baxdela (delafloxacin). Comparable as a small antibiotics-focused commercial-stage company navigating the same hospital-channel commercial dynamics relevant to a future ibezapolstat launch.
  • Nabriva Therapeutics: Biopharmaceutical company that developed and commercialized Xenleta (lefamulin), a pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable as a small-cap antibiotics developer with a hospital-channel launch approach and similar regulatory pathway profile.
  • Innoviva (formerly Entasis Therapeutics): Specialty pharmaceutical company that acquired Entasis Therapeutics and commercialized Xacduro (sulbactam-durlobactam) for Acinetobacter infections. Comparable as a focused anti-infectives developer targeting serious bacterial pathogens in the hospital channel.

Broad incumbents

  • Ferring Pharmaceuticals: Global specialty biopharmaceutical company that markets Rebyota (fecal microbiota, live-jslm), the first FDA-approved fecal microbiota product for prevention of rCDI. Comparable as an established CDI/rCDI player competing in Acurx's core therapeutic area.
  • Merck & Co. Large pharmaceutical company that markets Dificid (fidaxomicin), the leading branded macrocyclic antibiotic for C. difficile infection. Comparable as the entrenched standard-of-care competitor that any new CDI entrant (including ibezapolstat) must displace.
  • Astellas Pharma: Japanese multinational pharmaceutical company that co-markets Dificid (fidaxomicin) with Merck for CDI. Comparable as a broad incumbent selling an established CDI therapy competing with Acurx's lead candidate.

Emerging players

  • ContraFect Corporation: Clinical-stage biotechnology company developing direct lytic agents (lysins) and other anti-infectives for serious bacterial infections including drug-resistant Staphylococcus aureus. Comparable as a small emerging anti-infectives developer pursuing novel mechanisms against Gram-positive priority pathogens.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Acurx Pharmaceuticals social profiles

Digital presence

Acurx Pharmaceuticals compliance and trust

Trust signal

Compliance3 records

Acurx Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acurx Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Acurx Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acurx Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acurx Pharmaceuticals

What does Acurx Pharmaceuticals do?

Acurx Pharmaceuticals develops a new class of small-molecule antibiotics that inhibit the Gram-positive specific enzyme DNA polymerase IIIC (PolC), marketed under its Gram-Positive Selective Spectrum (GPSS®) approach. Its lead asset, oral ibezapolstat, is a Phase 3-ready antibiotic for C. difficile infection (CDI), and the preclinical ACX-375C program extends the same platform to systemically absorbed treatments for MRSA, VRE, drug-resistant Streptococcus pneumoniae, and inhalational anthrax.

Is Acurx Pharmaceuticals a public or private company?

Acurx Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Acurx Pharmaceuticals founded?

Acurx Pharmaceuticals was founded in 2018. It employs 1 to 10 people.

Where is Acurx Pharmaceuticals based?

Acurx Pharmaceuticals is headquartered in Staten Island, United States, in the North America region.

How does Acurx Pharmaceuticals make money?

One revenue line is on record: antibiotic commercialization.

Who are Acurx Pharmaceuticals's main competitors?

Direct peers on record are Seres Therapeutics, Iterum Therapeutics, Cidara Therapeutics, Melinta Therapeutics, Nabriva Therapeutics and Innoviva (formerly Entasis Therapeutics). Broad incumbents are Ferring Pharmaceuticals, Merck & Co. and Astellas Pharma. ContraFect Corporation is listed as an emerging player.

Does Acurx Pharmaceuticals have an API?

No public API is recorded for Acurx Pharmaceuticals.

What industry is Acurx Pharmaceuticals in?

Acurx Pharmaceuticals's product category is Infectious Disease Therapeutics (Antibiotics). Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains Acurx Pharmaceuticals at Buy, lowers price target to $11 from $31HC Wainwright & Co. maintained Acurx Pharmaceuticals at Buy and lowered its price target to $11 from $31, a 64.5% cut. The target implies an upside of 968% from the Nov 11 close of $1.03.Seeking AlphaAcurx Pharmaceuticals, Inc. (ACXP) Q3 2026 Earnings Call TranscriptAcurx Pharmaceuticals reported its third-quarter 2026 financial results on November 12, 2026, with CEO David Luci and CFO Robert Shawah presenting the company update and outlook. The company filed its Form 10-Q for the quarter, which is available on its website.BenzingaAcurx Pharmaceuticals Q3 2026 Earnings Call Transcript - Acurx Pharmaceuticals (NASDAQ:ACXP)Acurx Pharmaceuticals reported Q3 2026 net loss of $2.6 million and cash reserves of $9.7 million. The company began enrolling patients in the Pathfinder trial for recurrent C. diff infection, which is fully funded. Management remains confident in ibezapolstat's development and regulatory progress.TradingViewAcurx Pharmaceuticals Q3 2026 Earnings Call Is LiveAcurx Pharmaceuticals' Q3 2026 earnings call is live, with executives set to discuss financial results and answer analyst questions. The call may include surprise news, and management commentary on future demand, margins, or capital spending could move markets.ChartmillAcurx Pharmaceuticals (NASDAQ:ACXP) Posts Wider Q3 2026 LossAcurx Pharmaceuticals reported a Q3 2026 non-GAAP loss of $0.49 per share, wider than the estimated $0.3842 loss, while revenue remained at zero. The company, a late-stage antibiotic developer, posted no sales and no formal guidance, with shares down about 1.9% in premarket trading.PR NewswireAcurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business updateAcurx Pharmaceuticals reported Q3 2026 results with a net loss of $2.6 million and cash of $9.7 million. The company began enrolling patients in the PATHFINDER trial for recurrent CDI and received FDA guidance on its Phase 3 plan. It also advanced its DNA pol IIIC inhibitor pipeline with a new partnership with Leiden University.Stock TitanAcurx Sets Q3 2026 Earnings Call for Nov. 12Acurx Pharmaceuticals will discuss its third-quarter 2026 financial results on a conference call on November 12, 2026. The company will also provide a business update during the call.The future of tradingAcurx Pharmaceuticals Holds Annual Shareholder MeetingAcurx Pharmaceuticals shareholders elected David P. Luci and Jack H. Dean as directors at its October 16, 2026 annual meeting. Shareholders also ratified CohnReznick's appointment as independent registered public accounting firm for the fiscal year ending December 31, 2026.Ticker ReportAcurx Pharmaceuticals (NASDAQ:ACXP) Given “Buy” Rating at HC WainwrightHC Wainwright reaffirmed a buy rating on Acurx Pharmaceuticals with a $31 price target, while Weiss Ratings reiterated a sell rating. The stock traded at $1.28, down $0.06, and the company missed Q2 EPS estimates at -$0.53 versus -$0.38. Analysts expect a -2 EPS for the current year.YahooNew to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace GlobalThe Street will broadcast a program featuring BioVie, Acurx, Lantern Pharma, and SafeSpace Global at 6:30 PM ET. BioVie's CEO Cuong Do discusses Phase 2 ADDRESS-LC results for bezisterim in Long COVID, showing encouraging signals across clinical endpoints. The broadcast also covers Acurx's antibiotic development and Lantern's AI oncology platform.